Adolescent Idiopathic Scoliosis Clínica Corachan

TOMORROW´S HEALTHCARE, TODAY

EpiDisease SL is an innovative Spanish biotechnology company that has positioned itself as a pioneer in the research and development of clinical tools based on genetic and epigenetic advances. With over 10 years of dedication and effort, EpiDisease SL is committed to offering solutions that deliver the healthcare of the future, today. Its flagship product, ScoliGEN, is a clear example of its scientific and cutting-edge work, providing a test that enables more precise and personalized management of children with AIS.

At EpiDisease, science and health come together to transform medical care and provide patients with the best opportunities for their well-being.

At EpiDisease SL, we are excited to announce our collaboration with Clínica Corachan to offer cutting-edge in vitro diagnostic (IVD) tools: ScoliGEN and ScoliMIR. These innovative solutions, developed after 10 years of research and development, are specifically designed for patients with Adolescent Idiopathic Scoliosis (AIS) and their families. The availability of ScoliGEN and ScoliMIR at Clínica Corachan represents a global milestone in the integration of genetics and epigenetics in the management of scoliosis. These tools enable a precision and personalized approach, providing physicians with valuable information that can guide clinical decisions and improve outcomes and quality of life for children affected by this condition, and their families.

The Clínica Corachan Team

Since 2006, I have had the privilege of being part of the Hospital for Traumatology and Rehabilitation, where I have worked in the musculoskeletal rehabilitation section. During this time, I have led the vertebral deformities rehabilitation unit and have been actively involved in the management of rare diseases, such as collagenopathies.

On November 20, 2017, I joined Cap Clínic in the spinal cord injury unit, a team of highly skilled professionals recognized as a reference unit in Catalonia for patients with acute traumatic spinal cord injuries.

Regarding my academic background, I earned my PhD with honors (Cum Laude) from the Universitat Autònoma de Barcelona in 2012, with a focus on scoliosis. I also hold a Master’s degree in Basic Clinical Research from Harvard University.

Since 2011, I have been a residency tutor and a member of the hospital’s Clinical Research Ethics Committee (CEIC). I am also an associate professor at the Universitat Autònoma, teaching in the Physiotherapy degree program, and at the Universitat Ramon Llull in the Master’s in Health Sciences at Blanquerna. In addition, I am a member of the Scientific Committee of SOSORT, the International Society on Scoliosis Orthopaedic and Rehabilitation Treatment.

My professional journey reflects my commitment to rehabilitation and research, as well as my dedication to training new generations of healthcare professionals.

What are ScoliGEN and ScoliMIR?

ScoliGEN: This genetic tool assesses the genetic profile, identifying variants that may influence the progression of scoliosis. With this information, physicians can personalize treatment plans for each child and more effectively plan how the condition may evolve.

ScoliGEN is currently available

ScoliMIR: This epigenetic tool provides information on how environmental and lifestyle factors can affect gene expression related to scoliosis. With this information, physicians can diagnose and predict spinal progression, as well as monitor the effectiveness of conservative interventions—adapting, optimizing, and personalizing their approach to each case.

ScoliMIR is currently undergoing regulatory review. It is expected to be commercially available to patients in the fourth quarter of 2024.

A Personalized Approach for Each Patient

The collaboration between EpiDisease SL and Clínica Corachan not only represents an advancement in medical technology, but also reflects our shared commitment to improving the quality of life for young people with AIS. By bringing the power of genetics and epigenetics closer to treatment, we are empowering physicians and families to make informed, data-driven decisions. We are excited about the future and the positive impact that ScoliGEN and ScoliMIR will have on the lives of patients and their families. Together, we are paving the way toward a more effective and personalized management of adolescent idiopathic scoliosis. For more information on how these tools can benefit your family, please do not hesitate to contact Dr. Judith Sánchez Raya.